The CEO at Nottingham-headquartered Blinds 2go is cycling 300km in 24-hours in a bid to raise an impressive £10,000 for charity.
Nick Thomas will be among 160 riders participating in Duchenne UK’s challenging annual cycling event, the Duchenne Dash, covering the 300km distance from London to Paris in under 24-hours to raise a collective £1 million.
Duchenne UK is at the forefront of funding world-class research and care for those affected by Duchenne muscular dystrophy (DMD), a progressive condition primarily affecting young boys which causes progressive muscle degeneration and weakness.
Nick said: “DMD is a devastating condition which around 100 boys are born with each year. There is currently no cure, but the research Duchenne UK invest in is dramatically helping to advance treatments for those living with the disease – there are currently more than 500 boys participating in clinical trials which simply didn’t exist a decade ago.”
This is Nick’s seventh time competing in the Duchenne Dash, and his colleagues at Blinds 2go are supporting Nick to achieve his fundraising target by 17th May through completing an in-house cycling challenge, in which Blinds 2go will donate £1 for each kilometre the team complete, donating £500 if they achieve the full 300km. Blinds 2go are also a lead sponsor for the event.
Nick continued: “I’m honoured to be taking part in such a meaningful event. Last year was a challenge, starting with a 100km ride down to the south coast, then an uncomfortable overnight ferry crossing to the final 200km to Paris, but it was also an incredibly rewarding day and an emotional experience to ride alongside the loved ones of those coping with the challenges of DMD on a daily basis.
“This is my 7th Duchenne Dash, so I can talk from some experience – and I’m doing it because, in my view, Duchenne UK is a hugely deserving charity. The money we help raise will make such a difference and I’m grateful to everyone for their support!”
To support Nick, visit www.justgiving.com/team/nick-and-barts-duchenne-dash-2025
